Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSavills Regulatory News (SVS)

Share Price Information for Savills (SVS)

Share Price is delayed by 15 minutes
Get Live Data
819.00    -16.00 (-1.92%)
Bid:
823.00
Ask:
824.00
Spread: 1.00 (0.122%)
Market Cap: £1.13b
SVS Live PriceLast checked at - London Stock Exchange

Intraday Savills Share Chart

Director/PDMR Shareholding

29 Apr 2026 13:23

RNS Number : 4417C
Savills PLC
29 April 2026
Β 

SAVILLS PLC (THE "COMPANY")

TRANSACTION IN SHARES BY DIRECTORS AND PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMRS)

Β 

Vesting of Deferred Share Awards

Β 

Awards over ordinary shares of the Company under the Company's Deferred Share Plans have become unconditional in all respects following the end of their Deferred Period. In satisfaction of the Awards, the Trustees of the Group's Employee Benefit Trusts have effected the transfer of shares, following the settlement of associated tax liabilities through the sale of shares, to Directors and PDMRs of the Company as follows:

Β 

Director/ PDMR

Number of shares transferred

Number of shares disposed to cover tax liabilities associated with award vesting

Shareholding following this notification

Shareholding as a % of issued share capital

Simon Shaw (Director)

48,468

43,468

(shares sold to cover tax liabilities associated with award vesting only)

276,793

0.19%

Martin Fidden (PDMR)

8,664

-

34,046

0.02%

Alex Jeffrey (PDMR)

53,143

-

292,074

0.20%

Chris Lee (PDMR)

9,774

8,710

(shares sold to cover tax liabilities associated with award vesting only)

133,311

0.09%

Raymond Lee (PDMR)

35,671

-

211,852

0.14%

David Lipson (PDMR)

30,333

-

175,760

0.12%

James Sparrow (PDMR)

42,767

38,106

(shares sold to cover tax liabilities associated with award vesting only)

170,884

0.12%

Β 

The share price on disposal of all shares was Β£8.405 per share.

Β 

Β 

Β 

Β 

Grant of Deferred Share Awards

Β 

The Company announces that on 28 April 2026 the grant of the share-based element of 2025 profit share awards has been made under The Savills Deferred Share Bonus Plan to Directors and PDMRs as follows:

Β 

Director/ PDMR

Number of shares subject to The Savills Deferred Share Bonus Plan awarded to the Director/ PDMR on 28 April 2026

Simon Shaw (Director)

111,077

Chris Lee (PDMR)

22,155

David Lipson (PDMR)

9,105

James Sparrow (PDMR)

63,832

These awards have a Deferred Period of three years and are subject to rolled-up dividend shares whereby the number of shares awarded will be increased during the Deferred Period to reflect final and interim dividends declared during the Deferred Period.

Β 

The Company also announces that on 28 April 2026 the grant of an award has been made under The Savills Deferred Share Plan (No.2 Plan) to the following PDMR:

PDMR

Number of shares subject to The Savills Deferred Share Plan (No.2 Plan) awarded to the PDMR on 28 April 2026

Martin Fidden (PDMR)

119,758

13% of the above award has a Deferred Period of two years51% of the above award has a Deferred Period of three years36% of the above award has a Deferred Period of four years

70% of the award with a Deferred Period of three years and 100% of the award with a Deferred Period of four years is subject to the satisfaction of performance criteria relating to the financial performance of the Savills Asia Pacific ex-Greater China business over 2025 to 2027 (inclusive).

All tranches of the award are subject to rolled-up dividend shares whereby the number of shares awarded will be increased during the Deferred Periods to reflect final and interim dividends declared during the Deferred Periods.

Β 

The Company also announces that on 28 April 2026 the grant of an award has been made under The Schedule to The Savills Deferred Share Plan (No.2 Plan) to a PDMR based in the United States of America as follows:

Β 

PDMR

Number of shares subject to the Savills Deferred Share Plan awarded to the PDMR on 28 April 2026

David Lipson (PDMR)

44,214

One-third of Mr Lipson's award will vest on each of the three anniversaries subsequent to the date of grant subject to continued employment and performance. The award is subject to rolled-up dividend shares whereby the number of shares awarded will be increased during the Deferred Period to reflect final and interim dividends declared during the Deferred Periods.

Β 

Resulting beneficial interests under The Savills Deferred Share Bonus Plan and The Savills Deferred Share Plan (No.2 Plan) further to the above notifications are as follows:

Director/ PDMR

Resulting beneficial interest under The Savills Deferred Share Bonus Plan and The Savills Deferred Share Plan (No.2 Plan)

Simon Shaw (Director)

237,302

Martin Fidden (PDMR)

65,870

Alex Jeffrey (PDMR)

75,287

Chris Lee (PDMR)

48,348

David Lipson (PDMR)

105,062

James Sparrow (PDMR)

138,914

Β 

The information set out below is provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation No 596/2014.

1.

Details of the Director/ PDMR

Β 

(a)

Name

1. Simon Shaw

2. Martin Fidden

3. Alex Jeffrey

4. Chris Lee

5. Raymond Lee

6. David Lipson

7. James Sparrow

Β 

2.

Reason for the notification

Β 

(a)

Position/ status

1. Group Chief Executive/ Director

2. Chief Executive Officer - Asia Pacific (ex-Greater China)/ PDMR

3. Chief Executive Officer - Savills Investment Management/ PDMR

4. Group Legal Director & Company Secretary/ PDMR

5. Chief Executive - Hong Kong, Macau and Greater China/ PDMR

6. Chief Executive Officer - Savills North America/ PDMR

7. Chief Executive Officer - UK & EMEA/ PDMR

Β 

(b)

Initial notification/ Amendment

Β 

Initial notification

3.

Details of the issuer

Β 

(a)

Name

Savills plc

Β 

(b)

LEI

213800WXICGMBWHTA933

Β 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

(a)

Description of the Financial Instrument

Β 

Savills plc Ordinary Shares of 2.5p each

(b)

Identification code of the Financial Instrument

Β 

GB00B135BJ46

(c)

Nature of the transaction

Β 

1) Vesting of awards under the Company's Deferred Share Plans and sale of shares to cover tax liabilities associated with award vesting only

2) Grant of awards over Ordinary Shares in accordance with the Company's Deferred Share Plans

Β 

(d)

Price(s) and volume(s)

Β 

Price(s)

Volume(s)

Β 

1)

Acquisition

Β£nil per share

Β 

Β 

Β 

Β 

Β 

Disposal (to cover tax liabilities associated with award vesting only)

Β£8.405 per share

1. 92,253

2. 8,664

3. 53,143

4. 18,484

5. 35,671

6. 30,333

7. 80,873

Β 

1. 43,468

2. n/a

3. n/a

4. 8,710

5. n/a

6. n/a

7. 38,106

Β 

2)

Β£nil per share

1. 111,077

2. 119,758

3. n/a

4. 22,155

5. n/a

6. 53,316

7. 63,832

Β 

(e)

Aggregated information

Β 

- Aggregated volume

- Price

Β 

N/A

Β 

Β 

(f)

Date of the transaction

Β 

28 April 2026

(g)

Place of the transaction

Β 

Vesting of awards - Outside a trading venue

Β 

Sale of shares to cover tax liabilities associated with award vesting only - London Stock Exchange

Β 

Grant of awards - Outside a trading venue

Β 

Β 

Name of contact and telephone number for queries:

Chris Lee

Group Legal Director & Company Secretary

020 3107 5444

Β 

29 April 2026

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHZZGZDZLMGVZM
Date   Source Headline
19th Jun 20262:28 pmRNSDirector/PDMR Shareholding
18th Jun 202611:37 amRNSDirector/PDMR Shareholding
11th Jun 20263:20 pmRNSDirector/PDMR Shareholding
1st Jun 202611:29 amRNSTotal Voting Rights
22nd May 202610:09 amRNSDirector/PDMR Shareholding
14th May 202612:41 pmRNSResult of AGM
13th May 20264:16 pmRNSResult of AGM
13th May 20267:00 amRNSAGM Statement
12th May 20263:41 pmRNSDirector/PDMR Shareholding
7th May 20263:39 pmRNSDirector Declaration
29th Apr 20263:04 pmRNSReplacement - Director/PDMR Shareholding
29th Apr 20261:23 pmRNSDirector/PDMR Shareholding
28th Apr 20261:58 pmRNSDirector/PDMR Shareholding
13th Apr 20265:24 pmRNSHolding(s) in Company
13th Apr 20262:10 pmRNSDirector/PDMR Shareholding
7th Apr 20264:03 pmRNSAnnual Report and AGM Notice
1st Apr 202610:00 amRNSTotal Voting Rights
31st Mar 202612:55 pmRNSDirector/PDMR Shareholding
26th Mar 20268:57 amRNSDirector/PDMR Shareholding
24th Mar 202611:02 amRNSDirector/PDMR Shareholding
23rd Mar 20269:27 amRNSDirector/PDMR Shareholding
18th Mar 20263:47 pmRNSDirector/PDMR Shareholding
16th Mar 20262:33 pmRNSHolding(s) in Company
16th Mar 20262:33 pmRNSHolding(s) in Company
16th Mar 20262:00 pmRNSHolding(s) in Company
16th Mar 20262:00 pmRNSHolding(s) in Company
16th Mar 202611:51 amRNSDirector/PDMR Shareholding
16th Mar 202611:51 amRNSDirector/PDMR Shareholding
16th Mar 202611:49 amRNSDirector/PDMR Shareholding
16th Mar 202611:49 amRNSDirector/PDMR Shareholding
13th Mar 20261:34 pmRNSDirector/PDMR Shareholding
13th Mar 20261:32 pmRNSDirector/PDMR Shareholding
12th Mar 20267:26 amRNSSignificant Transaction
12th Mar 20267:26 amRNSSignificant Transaction
12th Mar 20267:08 amRNSFinal Results
11th Mar 20264:21 pmRNSDirector/PDMR Shareholding
11th Mar 20264:21 pmRNSDirector/PDMR Shareholding
5th Mar 20265:00 pmRNSHolding(s) in Company
2nd Mar 20269:11 amRNSTotal Voting Rights
25th Feb 202611:14 amRNSHolding(s) in Company
11th Feb 20264:07 pmRNSDirector/PDMR Shareholding
4th Feb 20265:29 pmRNSHolding(s) in Company
2nd Feb 20265:32 pmRNSTotal Voting Rights
19th Jan 20268:30 amRNSDirectorship change
15th Jan 20267:00 amRNSYear End Trading Update
13th Jan 20265:40 pmRNSDirector/PDMR Shareholding
13th Jan 202612:59 pmRNSHolding(s) in Company
2nd Jan 20263:00 pmRNSTotal Voting Rights
11th Dec 20252:00 pmRNSDirector/PDMR Shareholding
1st Dec 20259:49 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.